Immunotherapies  	Immunotherapies  	 NNP	B-NP
and  	and  	 CC	O
novel  	novel  	 NN	O
combinations 	combinations 	 NNS	O
:  	:  	 :	O
the  	the  	 DT	O
focus  	focus  	 NN	O
of  	of  	 IN	O
advances  	advances  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
melanoma  	melanoma  	 NN	B-NP
Since  	Since  	 IN	O
2011 	2011 	 CD	O
,  	,  	 ,	O
the  	the  	 DT	O
approval  	approval  	 NN	O
of  	of  	 IN	O
four  	four  	 CD	O
different  	different  	 JJ	O
classes  	classes  	 NNS	O
of  	of  	 IN	O
novel  	novel  	 NN	O
drugs  	drugs  	 NNS	O
( 	( 	 -LRB-	O
the  	the  	 DT	O
anti-CTLA-4  	anti-CTLA-4  	 JJ	B-NP
agent 	agent 	 NN	I-NP
,  	,  	 ,	O
ipilimumab 	ipilimumab 	 NNS	B-NP
;  	;  	 :	O
BRAF  	BRAF  	 NNP	B-NP
inhibitors  	inhibitors  	 NNS	I-NP
[ 	[ 	 -LRB-	O
BRAFi 	BRAFi 	 NNP	B-NP
] 	] 	 -RRB-	O
;  	;  	 :	O
MEK  	MEK  	 NNP	B-NP
inhibitors  	inhibitors  	 NNS	I-NP
[ 	[ 	 -LRB-	O
MEKi 	MEKi 	 NNP	B-NP
] 	] 	 -RRB-	O
;  	;  	 :	O
and  	and  	 CC	O
the  	the  	 DT	O
anti-PD-1  	anti-PD-1  	 JJ	B-NP
drug 	drug 	 NN	I-NP
,  	,  	 ,	O
pembrolizumab 	pembrolizumab 	 CD	B-NP
)  	)  	 -RRB-	O
has  	has  	 VBZ	O
revolutionized  	revolutionized  	 VBG	O
the  	the  	 DT	O
care  	care  	 NN	O
of  	of  	 IN	O
advanced  	advanced  	 JJ	O
melanoma 	melanoma 	 NN	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
the  	the  	 DT	O
disease  	disease  	 NN	O
becoming  	becoming  	 VBG	O
a  	a  	 DT	O
model  	model  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
new  	new  	 JJ	O
treatments  	treatments  	 NNS	O
for  	for  	 IN	O
other  	other  	 JJ	O
types  	types  	 NNS	O
of  	of  	 IN	O
cancer 	cancer 	 NN	O
.  	.  	 .	O
Further  	Further  	 JJ	B-NP
advances  	advances  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
melanoma  	melanoma  	 NN	B-NP
represented  	represented  	 VBD	O
some  	some  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
key  	key  	 JJ	B-NP
highlights  	highlights  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
European  	European  	 NNP	O
Society  	Society  	 NNP	O
of  	of  	 IN	O
Medical  	Medical  	 NNP	B-NP
Oncology  	Oncology  	 NNP	I-NP
( 	( 	 -LRB-	O
ESMO 	ESMO 	 NNP	B-NP
)  	)  	 -RRB-	O
2014  	2014  	 CD	O
congress 	congress 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
first  	first  	 JJ	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
trial  	trial  	 NN	O
of  	of  	 IN	O
an  	an  	 DT	O
anti-PD-1  	anti-PD-1  	 JJ	B-NP
agent  	agent  	 NN	I-NP
to  	to  	 TO	O
report  	report  	 VB	O
the  	the  	 DT	O
CA209-037  	CA209-037  	 JJ	B-NP
study  	study  	 NN	I-NP
included  	included  	 VBD	O
405  	405  	 CD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
metastatic  	metastatic  	 JJ	B-NP
melanoma  	melanoma  	 NNS	I-NP
previously  	previously  	 RB	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
ipilimumab  	ipilimumab  	 NNS	B-NP
who  	who  	 WP	O
were  	were  	 VBD	O
randomized  	randomized  	 CD	O
2 	2 	 CD	O
: 	: 	 :	O
1  	1  	 CD	O
to  	to  	 TO	O
receive  	receive  	 VB	O
nivolumab  	nivolumab  	 CD	B-NP
3  	3  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg  	kg  	 CD	I-NP
every  	every  	 DT	O
2  	2  	 CD	O
weeks  	weeks  	 NNS	O
or  	or  	 CC	O
investigator 	investigator 	 NN	B-NP
's  	's  	 POS	O
choice  	choice  	 NN	B-NP
chemotherapy 	chemotherapy 	 NN	I-NP
.  	.  	 .	O
Nivolumab  	Nivolumab  	 NNP	B-NP
was  	was  	 VBD	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
higher  	higher  	 JJR	O
response  	response  	 NN	B-NP
rate  	rate  	 NN	I-NP
than  	than  	 IN	O
chemotherapy  	chemotherapy  	 NN	O
and  	and  	 CC	O
was  	was  	 VBD	O
well  	well  	 RB	O
tolerated 	tolerated 	 JJ	O
,  	,  	 ,	O
with  	with  	 IN	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
mostly  	mostly  	 RB	O
low  	low  	 JJ	O
grade  	grade  	 NN	O
and  	and  	 CC	O
manageable  	manageable  	 JJ	O
using  	using  	 VBG	O
recommended  	recommended  	 JJ	O
treatment  	treatment  	 NN	B-NP
algorithms 	algorithms 	 NN	I-NP
.  	.  	 .	O
New  	New  	 JJ	O
data  	data  	 NNS	O
on  	on  	 IN	O
other  	other  	 JJ	O
immunotherapies 	immunotherapies 	 NN	B-NP
,  	,  	 ,	O
namely  	namely  	 RB	O
ipilimumab  	ipilimumab  	 JJ	O
and  	and  	 CC	O
pembrolizumab 	pembrolizumab 	 NN	B-NP
,  	,  	 ,	O
were  	were  	 VBD	O
also  	also  	 RB	O
reported 	reported 	 VBD	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
outside  	outside  	 JJ	O
of  	of  	 IN	O
immunotherapy 	immunotherapy 	 NN	B-NP
,  	,  	 ,	O
combination  	combination  	 NN	O
approaches  	approaches  	 VBZ	O
involving  	involving  	 VBG	O
targeted  	targeted  	 VBN	B-NP
agents  	agents  	 NNS	I-NP
were  	were  	 VBD	O
also  	also  	 RB	O
a  	a  	 DT	O
major  	major  	 JJ	O
focus  	focus  	 NN	O
of  	of  	 IN	O
ESMO  	ESMO  	 NNP	B-NP
this  	this  	 DT	O
year 	year 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
two  	two  	 CD	O
major  	major  	 JJ	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
studies  	studies  	 NNS	O
of  	of  	 IN	O
combined  	combined  	 JJ	O
BRAF  	BRAF  	 NNP	B-NP
inhibition  	inhibition  	 NN	I-NP
and  	and  	 CC	O
MEK  	MEK  	 NNP	B-NP
inhibition  	inhibition  	 VBZ	I-NP
being  	being  	 VBG	O
reported 	reported 	 VBN	O
.  	.  	 .	O
Overall 	Overall 	 RB	O
,  	,  	 ,	O
new  	new  	 JJ	O
clinical  	clinical  	 JJ	B-NP
trial  	trial  	 NN	I-NP
findings  	findings  	 NNS	I-NP
reported  	reported  	 VBD	O
at  	at  	 IN	O
ESMO  	ESMO  	 NNP	B-NP
further  	further  	 RB	O
endorse  	endorse  	 VB	O
the  	the  	 DT	O
view  	view  	 NN	O
that  	that  	 IN	O
melanoma 	melanoma 	 NN	B-NP
,  	,  	 ,	O
given  	given  	 VBN	O
the  	the  	 DT	O
continued  	continued  	 JJ	O
development  	development  	 NN	O
of  	of  	 IN	O
novel 	novel 	 NN	O
,  	,  	 ,	O
effective  	effective  	 JJ	O
compounds 	compounds 	 NN	O
,  	,  	 ,	O
can  	can  	 MD	O
accurately  	accurately  	 RB	O
be  	be  	 VB	O
described  	described  	 VBN	O
as  	as  	 IN	O
the  	the  	 DT	O
most  	most  	 RBS	O
dynamic  	dynamic  	 JJ	B-NP
field  	field  	 NN	I-NP
of  	of  	 IN	I-NP
oncology  	oncology  	 NN	I-NP
at  	at  	 IN	O
present 	present 	 JJ	O
.  	.  	 .	O
